Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized adjunctive azithromycin + metronidazole added to CDED in pediatric Crohn's disease
NL-OMON24884Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of azithromycin and metronidazole in Crohn's disease (3 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Feasibility of multicenter microbiome-guided trial and Potential efficacy in maintaining clinical remission. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
azithromycinmetronidazole
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON24884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24884.